KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Issued (2016 - 2025)

CRISPR Therapeutics AG's Shares Issued history spans 10 years, with the latest figure at $111.5 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 645.31% year-over-year to $111.5 million; the TTM value through Dec 2025 reached $398.1 million, up 32.39%, while the annual FY2025 figure was $398.1 million, 32.39% up from the prior year.
  • Shares Issued for Q4 2025 was $111.5 million at CRISPR Therapeutics AG, down from $282.2 million in the prior quarter.
  • Across five years, Shares Issued topped out at $282.2 million in Q3 2025 and bottomed at -$255.0 million in Q2 2024.
  • The 5-year median for Shares Issued is $10.6 million (2022), against an average of $51.7 million.
  • The largest YoY upside for Shares Issued was 5095.13% in 2024 against a maximum downside of 4618.91% in 2024.
  • A 5-year view of Shares Issued shows it stood at $181.9 million in 2021, then tumbled by 79.85% to $36.7 million in 2022, then dropped by 10.73% to $32.7 million in 2023, then tumbled by 54.28% to $15.0 million in 2024, then soared by 645.31% to $111.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Shares Issued are $111.5 million (Q4 2025), $282.2 million (Q3 2025), and -$4.2 million (Q2 2025).